ArticleWorld journal of clinical oncology2011
Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers.
Article in World journal of clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.World journal of gastroenterology · 2014Trial
- A novel, fully covered laser-cut nitinol stent with antimigration properties for nonresectable distal malignant biliary obstruction: a multicenter feasibility study.Gut and liver · 2013Trial
- Review
- Stent-in-Stent for Malign Obstruction: Should We Go Back to a Place Where We Were Happy?GE Portuguese journal of gastroenterology · 2020Article
- Article
- Enteral stents are safe and effective to relieve malignant gastric outlet obstruction in the elderly.Journal of gastrointestinal cancer · 2015Article
- Current status of chemotherapy for the treatment of advanced biliary tract cancer.The Korean journal of internal medicine · 2013Review
- Outcomes of endoscopic pyloric stenting in malignant gastric outlet obstruction: a retrospective study.BMC research notes · 2013Article
- Improvement of prognosis for unresectable biliary tract cancer.World journal of gastroenterology · 2013Article
- The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.Investigational new drugs · 2012Article
- Chemotherapy for the biliary tract cancers: moving toward improved survival time.Journal of gastrointestinal cancer · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gemcitabine chemotherapy has been the standard for advanced pancreatic cancer for more than a decade. New oral fluoropyrimidines such as S-1 and capecitabine are other key drugs. Gemcitabine plus erlotinib was the only combination therapy that significantly prolonged survival, although the effect was minimal. Little or no improvement in survival with recent molecular-targeted drugs might be attributed to the very high incidence of K-ras gene mutation in pancreatic cancer. Recently, the non-gemcitabine-based-regimen of FOLFIRINOX showed significantly greater overall survival compared with gemcitabine for the first time. For biliary tract cancer, gemcitabine plus cisplatin combination chemotherapy has been proved to significantly prolong survival and will become the standard therapy. Further improvement in survival is expected by the addition of cetuximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.